(Total Views: 554)
Posted On: 04/30/2021 6:55:39 PM
Post# of 155790
When I suggested LL to the NIH ACTIV-2 study.
This is in response to your email dated April 21, 2021, to the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH).
Thank you for sharing this information. Please be assured that NIH scientists are considering all potential therapies and are exploring the most promising treatment approaches for COVID-19.
You may be interested to know that the NIH Accelerating COVID-19 Therapeutic Interventions and Vaccines COVID-19 Clinical & Preclinical Candidate Compound Portal collects data on therapeutic candidates with near and long-term potential for testing against COVID-19. More information about this initiative may be found at https://www.nih.gov/research-training/medical...ives/activ and https://redcap.ncats.nih.gov/redcap/surveys/i...DAE87WPTE7.
Thank you for contacting NIAID.
Sincerely,
Kara M. Harris, MPH
Section Chief for Controlled Correspondence and Public Inquiries
Legislative Affairs and Correspondence Management Branch
Office of Communications and Government Relations
National Institute of Allergy and Infectious Diseases
National Institutes of Health
This is in response to your email dated April 21, 2021, to the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH).
Thank you for sharing this information. Please be assured that NIH scientists are considering all potential therapies and are exploring the most promising treatment approaches for COVID-19.
You may be interested to know that the NIH Accelerating COVID-19 Therapeutic Interventions and Vaccines COVID-19 Clinical & Preclinical Candidate Compound Portal collects data on therapeutic candidates with near and long-term potential for testing against COVID-19. More information about this initiative may be found at https://www.nih.gov/research-training/medical...ives/activ and https://redcap.ncats.nih.gov/redcap/surveys/i...DAE87WPTE7.
Thank you for contacting NIAID.
Sincerely,
Kara M. Harris, MPH
Section Chief for Controlled Correspondence and Public Inquiries
Legislative Affairs and Correspondence Management Branch
Office of Communications and Government Relations
National Institute of Allergy and Infectious Diseases
National Institutes of Health
(3)
(0)
